4.8 Article

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe

期刊

JOURNAL OF HEPATOLOGY
卷 72, 期 1, 页码 14-24

出版社

ELSEVIER
DOI: 10.1016/j.jhep.2019.08.027

关键词

Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH); Guidelines as topic; Health Policy; Review; Europe

资金

  1. EASL International Liver Foundation from Gilead Sciences Europe Ltd.
  2. Allergan Pharmaceutical International Ltd.
  3. Bristol-Myers-Squibb Company
  4. Pfizer Inc.
  5. Resoundant Inc.
  6. Miguel Servet
  7. Horizon 2020 Framework Program of the European Union [634413]
  8. IMI2 Program of the European Union [777377]

向作者/读者索取更多资源

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem worldwide and has become an important field of biomedical inquiry. We aimed to determine whether European countries have mounted an adequate public health response to NAFLD and non-alcoholic steatohepatitis (NASH). Methods: In 2018 and 2019, NAFLD experts in 29 European countries completed an English-language survey on policies, guidelines, awareness, monitoring, diagnosis and clinical assessment in their country. The data were compiled, quality checked against existing official documents and reported descriptively. Results: None of the 29 participating countries had written strategies or action plans for NAFLD. Two countries (7%) had mentions of NAFLD or NASH in related existing strategies (obesity and alcohol). Ten (34%) reported having national clinical guidelines specifically addressing NAFLD and, upon diagnosis, all included recommendations for the assessment of diabetes and liver cirrhosis. Eleven countries (38%) recommended screening for NAFLD in all patients with either diabetes, obesity and/or metabolic syndrome. Five countries (17%) had referral algorithms for follow-up and specialist referral in primary care, and 7 (24%) reported structured lifestyle programmes aimed at NAFLD. Seven (24%) had funded awareness campaigns that specifically included prevention of liver disease. Four countries (14%) reported having civil society groups which address NAFLD and 3 countries (10%) had national registries that include NAFLD. Conclusions: We found that a comprehensive public health response to NAFLD is lacking in the surveyed European countries. This includes policy in the form of a strategy, clinical guidelines, awareness campaigns, civil society involvement, and health systems organisation, including registries. Lay summary: We conducted a survey on non-alcoholic fatty liver disease with experts in European countries, coupled with data extracted from official documents on policies, clinical guidelines, awareness, and monitoring. We found a general lack of national policies, awareness campaigns and civil society involvement, and few epidemiological registries. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据